Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 ?g per 10⁶ cells in 100 ?l volume or 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Clone HK1.4 does not block the binding of clone RB6-8C5⁸.

Additional reported applications (for relevant formats of this clone) include: in vitro activation of T cells^1-3 and immunohistochemistry of frozen sections⁴.

1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (Activ)
2. Herold KC, et al. 1990. Diabetes 39:815. (Activ)
3. Havran WL, et al. 1988. J. Immunol. 140:1034 (Activ)
4. Flanagan K, et al. 2008. J. Immunol. 180:3874. (IHC)
5. Makaroff LE, et al. 2009. P. Natl. Acad. Sci. USA 106:4799. (FC)
6. Zuber J, et al. 2009. Genes Dev. 23:877. (FC) PubMed
7. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
8. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
9. Watson NB, et al. 2015. J Immunol. 194:2796. PubMed

1. Petersen B, et al. 2014. J Leukoc Biol. 95:809. PubMed
2. Zuchtriegel G, et al. 2016. PLoS Biol. 14: 1002459. PubMed
3. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
4. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
5. Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed
6. Zhou W, et al. 2019. Cell Syst. 0.597916667. PubMed
7. Fu R, et al. 2020. Sci Rep. 10:1455. PubMed
8. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
9. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
10. Zhang YS, et al. 2018. Cancer Biol Ther. 19:735. PubMed
11. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
12. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
13. Chen WS, et al. 2021. Cell Rep. 37:109974. PubMed
14. Park JG, et al. 2021. iScience. 24(9):102941. PubMed
15. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
16. Huai W, et al. 2019. J Exp Med. 216:772. PubMed
17. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
18. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
19. Davis FM, et al. 2019. Arterioscler Thromb Vasc Biol. 39:2353. PubMed
20. Dieterich LC, et al. 2019. International Journal of Cancer. 145(10):2804-2815. PubMed
21. Fachi JL, et al. 2020. J Exp Med. 217:00:00. PubMed
22. Nguyen CM, et al. 2019. Diabetes. 68:1499. PubMed
23. Gui J, et al. 2020. Nat Cancer. 1:603. PubMed
24. Yu X, et al. 2022. J Extracell Vesicles. 11:e12185. PubMed
25. Yoshida K, et al. 2022. Sci Rep. 12:17276. PubMed
26. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
27. Wu L, et al. 2022. Theranostics. 12:842. PubMed
28. Francis M, et al. 2017. Toxicol Sci. 155(1):182-195. PubMed
29. Wang F, et al. 2018. Carcinogenesis. 39:889. PubMed
30. Sun KT, et al. 2018. Front Physiol. 1.06875. PubMed
31. Zuo W, et al. 2022. Cell Death Discov. 8:257. PubMed
32. Gousopoulos E, et al. 2016. Am J Pathol. 186:2193-2203. PubMed
33. Zuber J, et al. 2009. Genes Dev. 1.567361111. PubMed
34. Mishra BB, et al. 2017. Nat Microbiol. 2:17072. PubMed
35. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
36. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
37. Burns JC, et al. 2020. eLife. 9:00. PubMed
38. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
39. Liu Z, et al. 2021. Immunity. 54(2):247-258.e7. PubMed
40. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
41. De Simone G, et al. 2021. Immunity. :. PubMed
42. Ding P, et al. 2022. Bone Res. 10:42. PubMed
43. Monaghan KL, et al. 2020. J Vis Exp. . PubMed
44. Guichard V, et al. 2017. Elife. 6:e27215. PubMed
45. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
46. Kar S, Colino J, Snapper C 2016. J Immunol. 196: 4204 - 4213. PubMed
47. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
48. Takaku S, et al. 2022. Evid Based Complement Alternat Med. 2022:6122955. PubMed
49. Winchell CG, et al. 2020. Front Immunol. 1.077083333. PubMed
50. Miyamoto T, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
51. Franklin DA, et al. 2020. JCI Insight. 5:. PubMed
52. Chen ST et al. 2019. Cell host & microbe. 25(4):602-616 . PubMed
53. Zhu K, et al. 2022. EMBO Rep. 23:e54499. PubMed
54. Hakim R, et al. 2021. J Neurosci. 41:8441. PubMed
55. Gu H, et al. 2021. Elife. 10:. PubMed
56. Chen C, et al. 2020. Cell Rep. 2136:30. PubMed
57. Yurdagul A Jr, et al. 2020. Cell Metabolism. 31(3):518-533.e10. PubMed
58. Kitamura K, et al. 2019. Int J Cardiol Heart Vasc. 23:100344. PubMed
59. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
60. Tang W, et al. 2021. Exp Ther Med. 22:1483. PubMed
61. Gong P, et al. 2022. Cell Death Discov. 8:466. PubMed
62. Ireland L, et al. 2020. Front Immunol. 11:297. PubMed
63. Wang X, et al. 2021. Theranostics. 11:209. PubMed
64. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
65. Chen J, et al. 2014. Cell Res. 24:1050. PubMed
66. Moreno M et al. 2014. The Journal of Neuroscience. 34(24):8175-85 . PubMed
67. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
68. Wang Y, et al. 2020. Immunity. 53(6):1168-1181.e7. PubMed
69. Aggarwal N, et al. 2021. Cell Rep. 37:110170. PubMed
70. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
71. Hohsfield LA, et al. 2021. Elife. 10:. PubMed
72. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
73. Francis M, et al. 2016. Toxicol Sci. 10.1093/toxsci/kfw226. PubMed
74. Denk F, et al. 2016. Cell Rep. 15: 1771-1781. PubMed
75. Koronyo Y, et al. 2015. Brain. 138: 2399-2422. PubMed
76. Younos I, et al. 2011. Int Immunopharmacol. 11:816. PubMed
77. Yá?ez A et al. 2017. Immunity. 47(5):890-902 . PubMed
78. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed

Ly-6C is expressed primarily on bone marrow myeloid populations, monocytes/macrophages, neutrophils, endothelial cells, and some T cell subsets. Ly-6C is also a marker of memory CD8⁺ T cells.

1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
2. Cerwenka A, et al. 1998. J. Immunol. 161:97.